Clinical trial

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30)…

NCT00094718 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00094718
Title Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults
Official title Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Collaborators Johns Hopkins Bloomberg School of Public Health
Status Completed
Phase Phase 1
Study type Interventional
Conditions West Nile Fever Encephalitis
Intervention type Biological
Interventions WN/DEN4-3'delta30, Placebo
Enrollment 56
Start date Feb 1, 2005
Primary completion Apr 1, 2005
Completion Apr 1, 2005
First posted Oct 22, 2004
Last update posted Jan 3, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies